The acute and chronic effects of the centrally active
oxotremorine analog,
BM-5, [N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)-
acetamide] were examined in rats and mice. In vivo studies in mice and rats indicated that this compound is a partial
muscarinic agonist with large regional differences in its efficacy:
BM-5 produced low
tremor in doses which evoke full salivary response. The maximal
tremor response to
BM-5 was much smaller than that produced by
oxotremorine, while the maximal salivary response to
BM-5 was greater than that evoked by
oxotremorine. The
tremor response to
BM-5 was bell-shaped, the peak dose being around 2 mg/kg. In contrast, the salivary response increased with increasing doses of
BM-5. The apparent
muscarinic antagonist properties of higher doses of
BM-5 were specific to the striatum in which
BM-5 (0.05-10 mg/kg) caused significant decreases in the level of
acetylcholine while these levels were unaltered in the cerebral cortex, hippocampus, and brainstem. Pretreatment of rats with
BM-5 (5 mg/kg) also prevented the increase in striatal
acetylcholine induced by
oxotremorine (0.75 mg/kg). Chronic treatment of mice with
BM-5 (0.2-2 mg/kg) for 14 days also showed that
BM-5 at higher doses, behaved as an antagonist, since it caused supersensitivity to
oxotremorine on the
tremor response. In addition, the number of receptor sites, as measured by binding of 3H-3-quinuclidinyl benzilate (3H-3-QNB), was increased in the striatum while no similar increase was observed in other brain areas.(ABSTRACT TRUNCATED AT 250 WORDS)